



Fall Group Meeting Chicago Specials

SEPTEMBER 18-20, 2025

Leukemia Committee

Leukemia Committee

Leadership

Chair:	Harry P. Erba, MD, PhD
Vice-Chair:	Anjali S. Advani, MD
Executive Officer:	Susan M. O'Brien, MD
Statisticians:	Megan Othus, PhD
.....	Anna Moseley, MS
.....	Matt Chansky, BS

Scientific Leadership

Translational Medicine:	Jerald P. Radich, MD
Pathology:	David R. Head, MD
Cytogenetics Liaison:	Min Fang, MD, PhD

Designates

Cancer Control:	Stephanie B. Tsai, MD
Veterans Affairs:	Tsewang Tashi, MD
Data Coordinators:	Roula Bustami
.....	Louise Highleyman, BA
.....	Cassie Villasin

Oncology Research Professionals:

CRA:	TBD
Nurse:	TBD
Patient Advocate:	Gail Sperling, MPH
Pharmaceutical Science:	Holly O. Chan, PharmD
.....	Ila M. Saunders, PharmD
Protocol Project Manager:	Amy Doyle
Protocol Project Manager:	Samantha Bankston (MyeloMATCH)
Clinical Trials Program Manager:	Sharon Palmer
Clinical Trials Program Manager:	Sarah Cantu (MyeloMATCH)

Time/Location

Friday, September 19, 2025 4:30 p.m. - 6:30 p.m.

Room: Water Tower (Concourse Level, West Tower)

Agenda

1. Updates in Leukemia Translational Medicine
2. Updates in CLL - Deb Stephens
3. Updates in AML/MyeloMATCH - Laura Michaelis
4. Updates in CML - Kendra Sweet
5. Updates in ALL - Kristen O'Dwyer

AML/MDS Studies

Active Studies

[**CTSU/A041701**](#), "A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy." Dr. L. Liesveld. Activated: 1/16/19. Closed: 9/16/24.

Closed Studies

[**S1612**](#), "A Randomized Phase II/III Trial of "Novel Therapeutics" Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older." Drs. L. Michaelis, R. Walter, S. Assouline, et al. Activated: 12/22/17; Complete: 6/26/24.

[**S0919**](#), "A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Poor-Risk Acute Myelogenous Leukemia (AML)." Dr. A. Advani. Re-Activated: 4/1/13; Closed: 9/15/17; Complete: 10/21/21.

[**S1203**](#), "A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)." Drs. Garcia-Manero and Pagel. Activated: 12/15/12; Closed: 11/4/15; Complete: 03/29/22.

ALL Studies

Active Studies

[**S1905**](#), "A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) / T-Cell Lymphoblastic Lymphoma (T-LBL)." Drs. A. Advani, N. Papadantonakis, and C. Yeung. Activated: 8/17/20.

[**CTSU/A041501**](#), "A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL." Dr. A. Advani. Activated: 6/1/17. Temporarily closed to accrual: 05/24/22.

Developing Studies

[**S2507**](#), "A Phase II Randomized Study of Blinatumomab with or without Revumenib for Patients with KMT2Ar B-ALL with persistent measurable residual disease (MRD)." Drs. I. Aldoss, A. Advani, W. Stock, J. McNeer, and C. Saygin.

Leukemia Committee

Closed Studies

S0333, "A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy." Drs. Forman and O'Donnell. Activated: 4/15/05; Closed: 11/1/09.

S1312, "A Phase I Study of Inotuzumab Ozogamicin in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia)." Drs. A. Advani and Liedtke. Activated: 4/1/14; Closed: 8/2/19.

S1318, "A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients \geq 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphocytic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients \geq 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL and Philadelphia-Chromosome-Like Signature (Ph-like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)." Drs. A. Advani and K. O'Dwyer. Activated: 1/12/15; Closed: 9/29/21.

CLL Studies

Active Studies

S1925, "Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL): EVOLVE CLL/SLL Study." Drs. D. Stephens, B. Hill, J. Pagel, et al. Activated: 12/14/20.

Developing Studies

S2504, "A Randomized Phase II Study of Pirtobrutinib Plus R-CHOP vs. R-CHOP for Patients with Previously Untreated Richter Transformation (RT)." Drs. M. Shadman, D. Stephens, and A. Danilov.

Closed Studies

CTSU/EA9161, "A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)." Dr. M. Shadman. Activated: 1/3/19. Closed: 4/30/21.

CTSU/A041702, "A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (\geq 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)." Dr. B. Hill. Activation: 1/4/19. Closed: 7/15/22.

CML Studies

Closed Studies

S1712, "A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease." Drs. K. Sweet and J. Radich. Activated: 7/20/18. Closed: 10/20/22.

MDS/MPN Studies

Developing Studies

SXXXX "A Phase II/III study of Nuvisertib and Decitabine-Cedazuridine for Myelodysplastic/myeloproliferative neoplasms (MDS/MPNs)." Drs. A. Coltoff, A. Gerds, and F. El Chaer.

MyeloMATCH

Active Studies

MYELOMATCH, "Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials." Drs. J. Radich and S. Jiwani. Activated: 05/16/24.

MM1YA-S01, "A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs. (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by myeloMATCH; A myeloMATCH Clinical Trial." Drs. P. Shami and T. Lin. Activated: 05/16/24.

MM1OA-S03, "A Randomized Phase II trial of C-DEC, Venetoclax, and Enasidenib Compared with Azacitidine and Venetoclax for Newly Diagnosed Older Adults with IDH2 mutant AML: A myeloMATCH Substudy." Drs. E. Huselton and U. Borate. Activated: 04/01/25

Developing Studies

MM1OA-S04, "A Phase II Trial of ASTX727 with Standard Duration Versus Shorter Duration of Venetoclax in Genomically Heterogenous AML Among Adults Aged 60 or Older and Less Fit for Intensive Therapy: A myeloMATCH Substudy." Drs. U. Borate and J. Jayanshu.

Leukemia Committee

MM1OA-S05, "A RAS-Activated Biomark Driven Phase II Study Evaluating the Addition of Tuspetinib to CPX-351 Induction TTherapy in Older Fit Adults with Acute Myeloid Leukemia: A myeloMATCH Substudy." Drs. J. Appelbaum, B. Jonas, and M. Konopleva.

Submitted Manuscripts

None this cycle

Clinical Trials Partnerships (CTP)

Active Studies

21CTP.LEUK01, "A Phase II Trial of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Participants with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia." Drs. Advani, Liedtke and Radich. Activated: 5/15/25

Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Spring 2025 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

Multiple Studies Guideline-Concordant Treatment among Adolescents and Young Adults (AYAs) with Acute Lymphoblastic Leukemia (ALL).
 Wolfson J, Grimes A, Nuno M, Ramakrishnan S, Dickens D, Roth M, Woods W, Barnett K, Alabi T, Beauchemin M, Levine J, Scialla M, Boayue K, Kerber C, Ponce O, Vargas S, Chang G, Stock W, Hershman D, Curran E, Advani A, O'Dwyer K, Luger S, Liu J, Freyer D, Sung L, Parsons S. *Journal of Clinical Oncology* Apr 30;9(3):pkaf033, 2025.
<https://pubmed.ncbi.nlm.nih.gov/40238217/>

Multiple Studies Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration. Tregnago C, Benetton M, Ries RE, Peplinski JH, Alonzo TA, Stirewalt D, Othus M, Duployez N, Sonneveld E, Abrahamsson J, Fogelstrand L, von Neuhoff N, Hasle H, Reinhardt D, Meshinchi S, Locatelli F, Pigazzi M. *Journal of Clinical Oncology* Mar 10;43(8):972-984, 2025. <https://pubmed.ncbi.nlm.nih.gov/39621969/>

N/A Biobanking and consent to future biospecimen use among adults enrolled in SWOG trials from 2000 to 2024. Olivieri DJ, Berridge-Green A, Othus M, Radich JP, Advani AS, Erba HP, Walter RB. *Blood Cancer Journal* May 3;15(1):85, 2025. <https://pubmed.ncbi.nlm.nih.gov/40319052/>

Leukemia Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	MM10A-S03	MM1YA-S01	MYELOMATCH	S1905	S1925	A041501	A041701	A041703
Banner University Medical Center - Tucson	-	-	2	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	5	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	2	7	4	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	1	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	2	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	1	-	-	-
Cedars-Sinai Medical Center	-	-	2	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	4	2	-	-	-
Duke University - Duke Cancer Institute LAPS	-	3	3	-	1	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	1	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	4	3	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	6	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	1	-	9	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	2	-	-	-	-	-
Henry Ford Hospital	-	-	4	-	3	-	4	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	-	2	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	2	-	-	-
Loyola University Medical Center	-	-	4	-	1	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	5	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	5	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	13	-	7	-	-	-
Montana Cancer Consortium NCORP	-	-	1	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	1	12	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	2	-
Northwestern University LAPS	-	2	26	-	1	3	1	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	4	-	-	-	-	-
Oregon Health and Science University	-	1	3	1	-	8	-	-
Pacific Cancer Research Consortium NCORP	-	-	17	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	1	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	2	-	-	-
Stanford Cancer Institute Palo Alto	-	-	-	-	-	8	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	4	2	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	4	3	-	1
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	2	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	1	24	-	-	1	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-	4	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	2	-	-	-	1
University of Kansas Cancer Center - MCA Rural MU NCORP	-	3	30	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	4	-	-	-	-	-
University of Rochester LAPS	-	2	35	3	13	7	27	3
University of Utah - Huntsman Cancer Institute LAPS	-	-	9	-	20	1	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	1	9	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	7	-	-	5	-	-
ALLIANCE	-	2	133	2	38	-	-	-
CCTG	-	-	39	-	12	-	-	-
ECOG-ACRIN	1	6	123	2	18	-	-	-
NRG	-	1	16	-	5	-	-	-
Total	2	23	551	20	152	44	38	5

Leukemia Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	A042001	EA9152	EA9171	EA9181	EA9213	MM10AE02	MM1YACTG01
Banner University Medical Center - Tucson	-	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	3	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	3	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	4	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	2	-	-	-
Intermountain Medical Center	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	2	-	1	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-
Northwestern University LAPS	1	-	-	4	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
Oregon Health and Science University	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-
Stanford Cancer Institute Palo Alto	3	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	12	-	-	-
UC San Diego Moores Cancer Center	-	-	-	1	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	2	-	-	-	-	-	1
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	4	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	2
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-
University of Rochester LAPS	4	-	-	9	-	2	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	3	-	-	-
Western States Cancer Research NCORP	-	-	2	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	2	3	2	1	-	1	-
ALLIANCE	-	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-
Total	12	3	4	45	3	4	3

